NCT00640965 - DP-VPA for Migraine Prophylaxis, a Pilot Efficacy Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

June 30, 2009

Study Completion Date

August 31, 2009

Conditions

Migraine

Interventions

DRUG

DP-VPA

DP-VPA dose escalation to 900mg, then continued for 8 weeks

DRUG

DP-VPA Placebo

Matching Placebo to Active, dose escalation, then continued for 8 weeks

Trial Locations (6)

Rambam Medical Center, Haifa

Chaim Sheba Medical Center, Tel Litwinsky

Wolfson Medical Center, Holon

Tel Aviv Sourasky Medical Center, Tel Aviv

Bnei Zion Medical Centre, Haifa

Beilinson Medical Centre, Petah Tikva